Maze Therapeutics Financial Statements
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
27.11+1.23 (+4.75%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics revenue and earnings
Maze Therapeutics reported a net loss of $131.1 million, compared with net income of $52.2 million a year earlier. Diluted earnings per share came in at -$3.05, down from $1.25.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Revenue | — | 167.50M |
| Revenue growth (YoY) | — | — |
| Operating Expenses | 142.90M | 109.91M |
| Research & Development | 108.45M | 83.50M |
| Operating Income | -142.90M | 57.59M |
| Pretax Income | -131.12M | 53.40M |
| Income Tax | 0 | 1.17M |
| Net Income | -131.12M | 52.23M |
| Net Income growth (YoY) | -351.04% | — |
| EPS (Basic) | -3.05 | 1.42 |
| EPS (Diluted) | -3.05 | 1.25 |
| Shares Outstanding (Basic) | 42.98M | 2.40M |
| Shares Outstanding (Diluted) | 42.98M | 2.73M |
| EBITDA | -140.50M | 60.88M |
| Operating Margin | — | 34.38% |
| Net Margin | — | 31.18% |
This table shows 2 annual periods of Maze Therapeutics's income statement, from FY 2025 back to FY 2024, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a income statement?